康缘药业：6名高管拟增持不少于12万股

Core Viewpoint - Kangyuan Pharmaceutical announced that several directors and the general manager plan to increase their holdings in the company starting from November 10, 2025, through a centralized bidding method on the Shanghai Stock Exchange [1] Group 1 - The directors and general manager involved in the share buyback include Yang Yongchun, Gao Haixin, Chen Xuebin, Liu Quan, Wang Chuanlei, and Pan Yu [1] - The total number of shares to be purchased is no less than 120,000, with each individual committing to buy at least 20,000 shares [1] - There is no price range set for this buyback plan, and the participants have committed not to reduce their holdings during the implementation period and the statutory period [1]